Endocyte (ECYT) (NSC) (PVA) (CNI) (DMAN) (EONGY) Downgraded

Endocyte (NASDAQ: ECYT), Norfolk Southern Corp. (NYSE: NSC), Penn Virginia (NYSE: PVA), Canadian National Railway (NYSE: CNI), DemandTec, Inc. (NASDAQ: DMAN) and E.ON AG (NASDAQ: EONGY) were downgraded by analysts.

Norfolk Southern Corp. (NSC) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.

Nippon Telegraph & Telephone Corp. (NTT) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating. They have a price target of $26.00 on the company.

Penn Virginia (PVA) was downgraded by CapitalOne from a “Buy” rating to a “Neutral” rating.

Canadian National Railway (CNI) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.

DemandTec, Inc. (DMAN) was downgraded by Raymond James (NYSE:RJF) from an “Outperform” rating to a “Market Perform” rating.

Endocyte (ECYT) was downgraded by Robert W. Baird from an “Outperform” rating to a “Neutral” rating.

E.ON AG (EONGY) was downgraded by WestLB to a “Neutral” rating.

Endocyte (ECYT) (AMPE) (PARDD) (CMED) (PTRY) (GMCR) Biggest NASDAQ Losers

Endocyte (NASDAQ:ECYT), Ampio Pharmaceutical (NASDAQ:AMPE), Poniard Pharmaceuticals (NASDAQ:PARDD), China Medical Technologies, Inc. (NASDAQ:CMED), Pantry (NASDAQ:PTRY) and Green Mountain Coffee Roasters Inc. (GMCR) were the biggest losers on the NASDAQ, Tuesday, December 13.

Endocyte (ECYT) ended the day down 65.60 percent, closing at $3.54. They traded in a range of $3.53 to $4.29. A total of 7,226,647 shares changed hands.

Ampio Pharmaceutical (AMPE) ended the day down 30.39 percent, closing at $5.13. They traded in a range of $5.05 to $7.19. A total of 461,802 shares changed hands.

Poniard Pharmaceuticals (PARDD) ended the day down 18.75 percent, closing at $3.25. They traded in a range of $3.23 to $4.00. A total of 21,059 shares changed hands.

China Medical Technologies, Inc. (CMED) ended the day down 13.33 percent, closing at $2.86. They traded in a range of $2.70 to $3.28. A total of 659,093 shares changed hands.

Pantry (PTRY) ended the day down 11.54 percent, closing at $10.50. They traded in a range of $9.52 to $10.83. A total of 1,425,606 shares changed hands.

Green Mountain Coffee Roasters Inc. (GMCR) ended the day down 11.33 percent, closing at $50.09. They traded in a range of $49.40 to $57.15. A total of 10,553,254 shares changed hands.

Oracle (ORCL) (WG) (BRO) (CNQR) (CRM) (ECYT) Get New Coverage

Oracle (NASDAQ: ORCL), Willbros Group, Inc. (NYSE: WG), Brown & Brown Inc. (NYSE: BRO), Concur Technologies, Inc. (NASDAQ: CNQR), Salesforce.com (NYSE: CRM) and Endocyte (NASDAQ: ECYT) getting new coverage from analysts.

Stifel Nicolaus initiated coverage on Willbros Group, Inc. (WG). They placed a “Buy” rating and a price target of $9.00 on the company.

Macquarie initiated coverage on Brown & Brown Inc. (BRO). They placed a “Neutral” rating on the company.

Morgan Keegan initiated coverage on Oracle (NASDAQ: ORCL). They placed an “Outperform” rating and a price target of $33.00 on the company.

Morgan Keegan initiated coverage on Concur Technologies, Inc. (CNQR). They placed a “Market Perform” rating and a price target of $42.00 on the company.

Morgan Keegan initiated coverage on Salesforce.com (CRM). They placed an “Outperform” rating and a price target of $165.00 on the company.

Cowen initiated coverage on Endocyte (ECYT). They placed an “Outperform” rating on the company.

Endocyte (ECYT) (UCTT) (WTI) (HSTM) (IIVI) (REDF) Make Big, Positive Moves

Endocyte, Inc., (NASDAQ: ECYT), Rediff.com India Limited (NASDAQ: REDF), Ultra Clean Holdings Inc. (NASDAQ: UCTT), W&T Offshore Inc. (NYSE: WTI), Healthstream Inc. (Nasdaq: HSTM) and II-VI Inc. (Nasdaq: IIVI) were trading up positive today, soaring in a range of 15 percent to over 30 percent in the case of Endocyte, Inc.

Endocyte, Inc. was up over 30 percent after announcing its plan to prepare two marketing authorization applications to the European Medicines Agency. These two marketing applications are for the company's lead drug candidate EC145 for the treatment of platinum-resistant ovarian cancer and its companion imaging diagnostic EC20 for patient selection. The filings will be based on the results of the randomized Phase 2 PRECEDENT trial and supported by a Phase 2 single agent EC145 clinical trial.

Rediff.com India Limited was up over 23.6 percent; it introduced Rediff Deal Ho Jaye!, a service targeting group deals. Rediff.com Deal Ho Jaye! offers will come from local merchants in each city. Consumers will be empowered to track upcoming promotions by subscribing to the Deal Ho Jaye! email newsletter or by SMS.

II-VI Inc. was trading up over 21 percent; it reported third-quarter EPS of $0.72, $0.19 above the analyst estimate of $0.53. Revenue for the quarter exceeded expectationg, reaching $130 million against the consensus estimate of $121.07 million. Guidance for EPS for the fourth quarter of 2011 was $0.68 - $0.73, against the consensus of $0.57. II-VI Inc. sees fourth quarter 2011 revenue of $129 - $134 million, against the consensus of $129.52 million. Full year 2011 EPS is expected to reach $2.58 - $2.63, against the consensus of $2.29. Full year 2011 revenue is projected to reach $500 - $505 million, against the consensus of $489.63 million.

Healthstream Inc. is trading almost 19 percent up; the company reported first quarter EPS of $0.07, $0.03 above the analyst estimate of $0.04. Revenue for the quarter came in at $18.5 million against the consensus estimate of $17.68 million.

W&T Offshore Inc. is trading over 16.0 higher; it reported first quarter EPS of $0.43, $0.12 above the analyst estimate of $0.31. Revenue for the quarter reached $210.9 million against the consensus estimate of $198.59 million.

Ultra Clean Holdings Inc. jumped over 15 percent; it reported first quarter EPS of $0.25, $0.04 above the analyst estimate of $0.21. Revenue for the quarter reached $126.7 million against the consensus estimate of $121.65 million. Ultra Clean Holdings Inc. projects second quarter EPS of $0.26-$0.29, against the consensus of $0.24. For the second quarter revenue estimates are from $128-$133 million, against consensus of $125.24 million.